Michael Zile to Electric Stimulation Therapy
This is a "connection" page, showing publications Michael Zile has written about Electric Stimulation Therapy.
Connection Strength
3.184
-
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
Score: 0.662
-
Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 07 07; 76(1):1-13.
Score: 0.630
-
First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. Am Heart J. 2018 10; 204:139-150.
Score: 0.550
-
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer; 28(2):320-328.
Score: 0.474
-
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct; 17(10):1066-74.
Score: 0.443
-
Baroreflex activation therapy with the Barostim? device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022 09; 24(9):1665-1673.
Score: 0.181
-
Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. Int J Cardiol. 2018 Sep 01; 266:187-192.
Score: 0.135
-
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):487-496.
Score: 0.110